Because of these effects, Rag1 deletion is used in mouse models of disease to impair
T cell and
B cell development, and functionally deletes mature T and B cells from the immune system. In humans, RAG deficiency was first recognised as a form of immune dysregulation known as
Omenn syndrome. RAG deficiency is considered an
autosomal recessive disease. The disorder is generally identified in infants. Complete loss-of-function in RAG1/2, the main components responsible for V(D)J recombination activity, produces severe immunodeficiency in humans. Hypomorphic RAG variants can retain partial recombination activity and result in a distinct phenotype of combined immunodeficiency with granuloma and/or autoimmunity (CID-G/A), as well as other milder forms, such as antibody deficiency, Idiopathic CD4+ T lymphopenia or vasculitis. RAG deficiency can be measured by in vitro quantification of recombination activity. 71 RAG1 and 39 RAG2 variants have been functionally assayed to date (2019) (less than 10% of the potential point mutations that may cause disease). However, top candidate variants have been ranked by their predicted clinical relevance. == Use in phylogenetics ==